For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Tafamidis and the formulated version represents a genuine change. These groundbreaking therapies protect the transthyretin protein, slowing its damaging build-up and alleviating the burden of the disease . Patients are now reporting posit… Read More